Navigation Links
Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis
Date:7/15/2011

EDISON, N.J., July 15, 2011 /PRNewswire/ -- Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. This group of drugs has had a controversial history, starting with Baycol, a drug similar to Crestor and Zocor, touted as a "super statin" before its recall from the market. Despite numerous objections from medical researchers and reputable consumer groups due to safety concerns, the drug was approved by the FDA in August of 2003, and launched a month later. Even before their FDA approval, these drugs showed signs of being linked to serious muscle and kidney problems, including the potentially fatal, muscle-destroying condition rhabdomyolysis.

Zocor and Crestor are strongly marketed by their parent companies, Merck and AstraZeneca respectively. By early 2004, 27% of all new prescriptions for statin drugs were for Crestor. The Wall Street Journal reported:

"AstraZeneca sales force (Crestor) was making more calls to doctors than any of its competitors. Beginning in late February, reflecting the sales calls, new prescriptions of Crestor began to rise and overtook Lipitor by the beginning of March 20."

This style of pharmaceutical marketing is so effective that in 2010, the statin Lipitor was the #1 selling drug in America by unit, with Crestor at #6.

Warning-sign side effects include:

  • muscle pain, tenderness, or weakness
  • lack of energy
  • fever
  • chest pain
  • yellowing of the skin or eyes
  • pain in the upper right part of the abdomen
  • nausea
  • extreme tiredness
  • unusual bleeding or bruising
  • loss of appetite
  • flu-like symptoms
  • sore throat, chills, or other signs of infection
  • rash
  • hives
  • itching
  • difficulty breathing or swallowing
  • swelling of the face, throat tongue, lips, eyes, hands, feet, ankles, or lower legs
  • hoarseness
  • numbness or tingling in the fingers or toes

These drugs are extremely profitable for the companies that market, produce, and sell them, as well as potentially, extremely dangerous for those who pay for and consume them. Lawsuits are currently being brought against the companies producing Zocor and Crestor. Many people across America have experienced unnecessary and dangerous side-effects as a result of these drugs. One of the law offices conducting lawsuits into both Crestor and Zocor is Eichen Crutchlow Zaslow & McElroy, LLP located in Edison, New Jersey and Toms River, New Jersey, a legal group with a history of award-winning legal services in the tri-state area and nationally in matters involving catastrophic personal injury, mass torts, medical malpractice, class actions, and consumer fraud litigation. Those who have been injured by Crestor or Zocor use should not hesitate to contact a lawyer.

Contact: Angela McKillop
Amckillop@njadvocates.com
NJAdvocates.com
Tel: (732) 777-0100
Fax: (732) 248-8273


'/>"/>
SOURCE Eichen Crutchlow Zaslow & McElroy, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
6. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
7. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
8. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
9. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study
11. Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... 2017 Kineta, Inc., a biotechnology company focused on ... Vice President of R&D and Head of Virology Kristin Bedard ... for the Northwest and Beyond meeting sponsored by Life ... 2017 from 8:30-10:30 AM PDT at the Agora Conference Center ... Dr. Bedard will be joined by other leaders in infectious ...
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 2017 , ... As we celebrate our nation’s independence, many Americans will gather ... perfect time to celebrate National Hot Dog Month. The National Hot Dog and ... July 4th alone and while they enjoy many different kinds of hot dogs, research ...
(Date:6/28/2017)... ... 2017 , ... Continually at the forefront of sweetener innovation, ... received the Non-GMO Project Verified seal. All five flavors of the plant-based, sugar-free ... verification for non-GMO foods and products in North America. , Available in Caramel, ...
(Date:6/28/2017)... ... 28, 2017 , ... Hayes, Inc., a leading provider of ... speaker lineup* for its second annual Client Symposium. Joining the symposium this year ... Fernandez of Privia Health; and Lisa Tourville of Anthem. , “We are ...
(Date:6/28/2017)... ... June 28, 2017 , ... David B. Sosin, a founding partner at the ... the post of 2nd Vice President for the Illinois State Bar Association , in ... ISBA’s 3rd Vice President in 2016 following a state-wide election and served in that capacity ...
(Date:6/28/2017)... Clara, CA (PRWEB) , ... June 28, 2017 , ... ... hosting a free AFM Luncheon for all SEMICONWest attendees and Park customers ... luncheon will feature talks from Dr. Sang-il Park, Chairman & CEO of Park Systems, ...
Breaking Medicine News(10 mins):